JP2015509742A - 眼科用フィルタの構成を決定する方法 - Google Patents
眼科用フィルタの構成を決定する方法 Download PDFInfo
- Publication number
- JP2015509742A JP2015509742A JP2014545428A JP2014545428A JP2015509742A JP 2015509742 A JP2015509742 A JP 2015509742A JP 2014545428 A JP2014545428 A JP 2014545428A JP 2014545428 A JP2014545428 A JP 2014545428A JP 2015509742 A JP2015509742 A JP 2015509742A
- Authority
- JP
- Japan
- Prior art keywords
- range
- user
- parameters
- optical
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000003287 optical effect Effects 0.000 claims abstract description 252
- 239000000758 substrate Substances 0.000 claims abstract description 136
- 238000001914 filtration Methods 0.000 claims abstract description 83
- 230000005540 biological transmission Effects 0.000 claims abstract description 62
- 210000001747 pupil Anatomy 0.000 claims abstract description 14
- 230000002207 retinal effect Effects 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 201000010099 disease Diseases 0.000 claims description 56
- 208000010412 Glaucoma Diseases 0.000 claims description 38
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 36
- 208000002780 macular degeneration Diseases 0.000 claims description 36
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 27
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 238000001429 visible spectrum Methods 0.000 claims description 19
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 17
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 15
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 15
- 230000004438 eyesight Effects 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 11
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims description 10
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims description 10
- 230000006866 deterioration Effects 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 210000000695 crystalline len Anatomy 0.000 description 125
- 238000010521 absorption reaction Methods 0.000 description 83
- 239000000463 material Substances 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 150000004032 porphyrins Chemical class 0.000 description 22
- 210000003994 retinal ganglion cell Anatomy 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 239000010408 film Substances 0.000 description 20
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 18
- 230000000903 blocking effect Effects 0.000 description 17
- 210000001525 retina Anatomy 0.000 description 16
- 239000000975 dye Substances 0.000 description 15
- 239000000049 pigment Substances 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 13
- 239000011358 absorbing material Substances 0.000 description 13
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000002093 peripheral effect Effects 0.000 description 12
- 229960003987 melatonin Drugs 0.000 description 11
- 239000004038 photonic crystal Substances 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 208000001491 myopia Diseases 0.000 description 10
- 206010061323 Optic neuropathy Diseases 0.000 description 9
- 208000020911 optic nerve disease Diseases 0.000 description 9
- 230000000737 periodic effect Effects 0.000 description 9
- 231100000760 phototoxic Toxicity 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 8
- 230000004456 color vision Effects 0.000 description 8
- 230000009977 dual effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000009931 harmful effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 7
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 7
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 206010015037 epilepsy Diseases 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 description 7
- 239000005020 polyethylene terephthalate Substances 0.000 description 7
- 239000004814 polyurethane Substances 0.000 description 7
- 239000010409 thin film Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 6
- 206010034972 Photosensitivity reaction Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000027288 circadian rhythm Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- 208000007578 phototoxic dermatitis Diseases 0.000 description 6
- 231100000018 phototoxicity Toxicity 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001627 detrimental effect Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000012994 photoredox catalyst Substances 0.000 description 5
- -1 polyethylene terephthalate Polymers 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 239000006117 anti-reflective coating Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 229930002868 chlorophyll a Natural products 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 229960005375 lutein Drugs 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- 230000005043 peripheral vision Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- YLYPIBBGWLKELC-RMKNXTFCSA-N 2-[2-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=CC(=C(C#N)C#N)C=C(C)O1 YLYPIBBGWLKELC-RMKNXTFCSA-N 0.000 description 2
- UWAUSMGZOHPBJJ-UHFFFAOYSA-N 4-nitro-1,2,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1N=NO2 UWAUSMGZOHPBJJ-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- PJOJZHHAECOAFH-UHFFFAOYSA-N 5,10,15,20-tetrakis(4-methoxyphenyl)-21,23-dihydroporphyrin Chemical compound COc1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc([nH]2)c(-c2ccc(OC)cc2)c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc1[nH]2 PJOJZHHAECOAFH-UHFFFAOYSA-N 0.000 description 2
- ZHBOFZNNPZNWGB-UHFFFAOYSA-N 9,10-bis(phenylethynyl)anthracene Chemical compound C1=CC=CC=C1C#CC(C1=CC=CC=C11)=C(C=CC=C2)C2=C1C#CC1=CC=CC=C1 ZHBOFZNNPZNWGB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000004983 Polymer Dispersed Liquid Crystal Substances 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000038018 age-related macular disease Diseases 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- 230000003373 anti-fouling effect Effects 0.000 description 2
- 201000009310 astigmatism Diseases 0.000 description 2
- KSCQDDRPFHTIRL-UHFFFAOYSA-N auramine O Chemical compound [H+].[Cl-].C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 KSCQDDRPFHTIRL-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229930002869 chlorophyll b Natural products 0.000 description 2
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- KCDCNGXPPGQERR-UHFFFAOYSA-N coumarin 343 Chemical compound C1CCC2=C(OC(C(C(=O)O)=C3)=O)C3=CC3=C2N1CCC3 KCDCNGXPPGQERR-UHFFFAOYSA-N 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- OVPVVOAYSGVQSZ-UHFFFAOYSA-L lucifer yellow carbohydrazide dye(2-) Chemical compound [O-]S(=O)(=O)C1=CC(C(N(NC(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N OVPVVOAYSGVQSZ-UHFFFAOYSA-L 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011022 opal Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 238000001020 plasma etching Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000004296 scotopic vision Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000411 transmission spectrum Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 208000013021 vision distortion Diseases 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XPOIQAIBZGSIDD-UHFFFAOYSA-M 2-[4-(dimethylamino)styryl]-1-methylpyridinium iodide Chemical compound [I-].C1=CC(N(C)C)=CC=C1\C=C\C1=CC=CC=[N+]1C XPOIQAIBZGSIDD-UHFFFAOYSA-M 0.000 description 1
- UQASJTNIEXIESH-UHFFFAOYSA-N 5,10,15,20-tetrakis(2,6-dichlorophenyl)-21,23-dihydroporphyrin Chemical compound Clc1cccc(Cl)c1-c1c2ccc(n2)c(-c2c(Cl)cccc2Cl)c2ccc([nH]2)c(-c2c(Cl)cccc2Cl)c2ccc(n2)c(-c2c(Cl)cccc2Cl)c2ccc1[nH]2 UQASJTNIEXIESH-UHFFFAOYSA-N 0.000 description 1
- GTZCNONABJSHNM-UHFFFAOYSA-N 5,10,15,20-tetraphenyl-21,23-dihydroporphyrin zinc Chemical compound [Zn].c1cc2nc1c(-c1ccccc1)c1ccc([nH]1)c(-c1ccccc1)c1ccc(n1)c(-c1ccccc1)c1ccc([nH]1)c2-c1ccccc1 GTZCNONABJSHNM-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DEMILCWIXNOUPD-UHFFFAOYSA-N C1(=C(C(=CC(=C1)C)C)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C5=C(C=C(C=C5C)C)C)N4)C4=C(C=C(C=C4C)C)C)N3)C3=C(C=C(C=C3C)C)C)=N2)C.[Mg] Chemical compound C1(=C(C(=CC(=C1)C)C)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C5=C(C=C(C=C5C)C)C)N4)C4=C(C=C(C=C4C)C)C)N3)C3=C(C=C(C=C3C)C)C)=N2)C.[Mg] DEMILCWIXNOUPD-UHFFFAOYSA-N 0.000 description 1
- FIZZUEJIOKEFFZ-UHFFFAOYSA-M C3-oxacyanine Chemical compound [I-].O1C2=CC=CC=C2[N+](CC)=C1C=CC=C1N(CC)C2=CC=CC=C2O1 FIZZUEJIOKEFFZ-UHFFFAOYSA-M 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 229920000106 Liquid crystal polymer Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000001015 X-ray lithography Methods 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- BVPNNDKPBSRHPV-UHFFFAOYSA-L [Cl-].[Mn+3].C1=CC(S(=O)(=O)[O-])=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 Chemical compound [Cl-].[Mn+3].C1=CC(S(=O)(=O)[O-])=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 BVPNNDKPBSRHPV-UHFFFAOYSA-L 0.000 description 1
- PIMVUSLRFVRIMZ-UHFFFAOYSA-N [Mg].C(C)C1=C(C=2C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C1N2)CC)CC)N4)CC)CC)N3)CC)CC)CC Chemical compound [Mg].C(C)C1=C(C=2C=C3C(=C(C(=CC=4C(=C(C(=CC5=C(C(=C(N5)C=C1N2)CC)CC)N4)CC)CC)N3)CC)CC)CC PIMVUSLRFVRIMZ-UHFFFAOYSA-N 0.000 description 1
- BXDIOBSIZYRUED-UHFFFAOYSA-M [Na+].C1=CC(S(=O)(=O)[O-])=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 Chemical compound [Na+].C1=CC(S(=O)(=O)[O-])=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 BXDIOBSIZYRUED-UHFFFAOYSA-M 0.000 description 1
- BVNNHPHCYCICRL-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].S(=O)(=O)([O-])C1=CC=C(C=C1)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.S(=O)(=O)([O-])C2=CC=C(C=C2)C2=C1NC(=C2)C=C2C=CC(=N2)C=C2C=CC(N2)=CC=2C=CC(N2)=C1.S(=O)(=O)([O-])C1=CC=C(C=C1)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.S(=O)(=O)([O-])C2=CC=C(C=C2)C2=C1NC(=C2)C=C2C=CC(=N2)C=C2C=CC(N2)=CC=2C=CC(N2)=C1 Chemical compound [Na+].[Na+].[Na+].[Na+].S(=O)(=O)([O-])C1=CC=C(C=C1)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.S(=O)(=O)([O-])C2=CC=C(C=C2)C2=C1NC(=C2)C=C2C=CC(=N2)C=C2C=CC(N2)=CC=2C=CC(N2)=C1.S(=O)(=O)([O-])C1=CC=C(C=C1)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.S(=O)(=O)([O-])C2=CC=C(C=C2)C2=C1NC(=C2)C=C2C=CC(=N2)C=C2C=CC(N2)=CC=2C=CC(N2)=C1 BVNNHPHCYCICRL-UHFFFAOYSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003667 anti-reflective effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- DNZSHSJERXNJGX-UHFFFAOYSA-N chembl3040240 Chemical compound C1=CC(C(=C2C=CC(N2)=C(C=2C=CN=CC=2)C=2C=CC(N=2)=C(C=2C=CN=CC=2)C2=CC=C3N2)C=2C=CN=CC=2)=NC1=C3C1=CC=NC=C1 DNZSHSJERXNJGX-UHFFFAOYSA-N 0.000 description 1
- VFHDWGAEEDVVPD-UHFFFAOYSA-N chembl507897 Chemical compound C1=CC(O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(O)=CC=1)=C1C=CC(=N1)C(C=1C=CC(O)=CC=1)=C1C=CC(N1)=C1C=2C=CC(O)=CC=2)=C2N=C1C=C2 VFHDWGAEEDVVPD-UHFFFAOYSA-N 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 230000003098 cholesteric effect Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- USIHEAIUCFLGKK-UHFFFAOYSA-N cobalt(2+) 5,10,15,20-tetrakis(4-methoxyphenyl)-21,23-dihydroporphyrin Chemical compound [Co++].COc1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc([nH]2)c(-c2ccc(OC)cc2)c2ccc(n2)c(-c2ccc(OC)cc2)c2ccc1[nH]2 USIHEAIUCFLGKK-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- VMJKUPWQKZFFCX-UHFFFAOYSA-N coumarin 504 Chemical compound C1CCC2=C(OC(C(C(=O)OCC)=C3)=O)C3=CC3=C2N1CCC3 VMJKUPWQKZFFCX-UHFFFAOYSA-N 0.000 description 1
- 238000009195 dark therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000005276 holographic polymer dispersed liquid crystals (HPDLCs) Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000025 interference lithography Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron(III) chloride Substances Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
- OOUCNTOGOJHBAQ-UHFFFAOYSA-K manganese(3+) 2,3,7,8,12,13,17,18-octaethyl-21,23-dihydroporphyrin trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Mn+3].N1C(C=C2C(=C(CC)C(C=C3C(=C(CC)C(=C4)N3)CC)=N2)CC)=C(CC)C(CC)=C1C=C1C(CC)=C(CC)C4=N1 OOUCNTOGOJHBAQ-UHFFFAOYSA-K 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 230000004386 ocular blood flow Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 229960000286 proflavine Drugs 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FDJUBNCEVCSIAV-UHFFFAOYSA-N tetrakis(o-aminophenyl)porphyrin Chemical compound NC1=CC=CC=C1C(C1=CC=C(N1)C(C=1C(=CC=CC=1)N)=C1C=CC(=N1)C(C=1C(=CC=CC=1)N)=C1C=CC(N1)=C1C=2C(=CC=CC=2)N)=C2N=C1C=C2 FDJUBNCEVCSIAV-UHFFFAOYSA-N 0.000 description 1
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical class C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C13/00—Assembling; Repairing; Cleaning
- G02C13/003—Measuring during assembly or fitting of spectacles
- G02C13/005—Measuring geometric parameters required to locate ophtalmic lenses in spectacles frames
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/104—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses having spectral characteristics for purposes other than sun-protection
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/105—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses having inhomogeneously distributed colouring
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/107—Interference colour filters
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C7/108—Colouring materials
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Geometry (AREA)
- Optical Filters (AREA)
- Prostheses (AREA)
- Eyeglasses (AREA)
- Eye Examination Apparatus (AREA)
Abstract
Description
Claims (19)
- 使用者のための光学基板を含む光デバイスの干渉フィルタリング手段の構成を決定する方法であって、
前記使用者の少なくとも1つの主視線、前記光学基板と前記使用者の眼との間の前記距離、前記使用者の前記眼の網膜部位のサイズ及び/又は瞳孔サイズを表す第1セットのパラメータを用意するステップと、
前記第1セットのパラメータに基づき第1の選択入射角範囲を決定するステップと、
前記使用者のために、少なくとも部分的に阻止されるべき波長の範囲を特徴付ける第2セットのパラメータを用意するステップと、
少なくとも部分的に阻止されるべき入射光の第1の選択波長範囲を前記第2セットのパラメータに基づき決定するステップと、
第1の選択的干渉フィルタリング手段及び前記光学基板の表面の第1のゾーンを前記第1の選択入射角範囲及び前記第1の選択波長範囲に基づき構成するステップであって、前記第1の選択的干渉フィルタリング手段が、前記第1の選択入射角範囲内の前記第1のゾーンに入射する前記入射光の第1の選択波長範囲の透過を第1の除去率において阻止するように動作可能であるように構成するステップと、
を含む、方法。 - 前記第1セットのパラメータ及び/又は前記第2セットのパラメータが、前記使用者が前記眼の劣化に罹患している、又は前記眼の劣化から保護されるべきであるかどうかなどの前記使用者の生理学的パラメータを更に含む、請求項1に記載の方法。
- 前記眼の前記劣化が、特に、緑内障、糖尿病性網膜症、レーバー遺伝性視神経症、加齢黄斑変性(AMD)、スタルガルド病、網膜色素変性又はベスト病などの酸化ストレス型の変性メカニズムに起因する、請求項1又は2に記載の方法。
- 前記使用者の少なくとも1つの更なる主視線、前記光学基板と前記使用者の前記眼との間の前記距離、前記使用者の前記眼の窩を中心とした網膜部位のサイズ及び/又は前記使用者の前記眼の前記瞳孔サイズを画定する少なくとも1つの更なる第1セットのパラメータを用意するステップと、
前記又は各更なる第1セットのパラメータに対し、各々の選択入射角範囲を前記各々の更なる第1セットのパラメータに基づき決定するステップと、
前記使用者のために、少なくとも部分的に阻止されるべき少なくとも1つの更なる波長範囲を特徴付ける少なくとも1つの更なる第2セットのパラメータを用意するステップと、
前記又は各更なる第2セットのパラメータに対し、少なくとも部分的に阻止されるべき入射光の各々の選択波長範囲を前記各々の更なる第2セットのパラメータに基づき決定するステップと、
前記又は各更なる第1セットのパラメータ及び更なる第2セットのパラメータに対し、
各々の更なる選択的干渉フィルタリング手段及び前記光学基板の前記表面の各々の更なるゾーンを前記各々の選択入射角範囲及び前記各々の選択波長範囲に基づき構成するステップであって、前記各々の更なる選択的干渉フィルタリング手段が、前記各々の選択入射角範囲内において前記各々の更なるゾーンに入射する入射光の前記各々の選択波長範囲の透過を各々の更なる除去率において阻止するように動作可能であるように構成するステップと、
を更に含む、請求項1〜3のいずれか一項に記載の方法。 - 前記又は各それぞれの選択入射角範囲が前記第1の選択入射角範囲と異なる、請求項4に記載の方法。
- 前記又は各それぞれの選択的波長範囲が前記第1の選択波長範囲と実質的に同じである、請求項4又は5に記載の方法。
- 前記第1の除去率が、10%〜100%、好ましくは、30%〜100%の範囲内である、請求項1〜6のいずれか一項に記載の方法。
- 各更なる除去率が前記第1の除去率と異なる、請求項7に記載の方法。
- 前記光デバイスが光学レンズであり、前記方法が、前記第1のゾーンを着用者の前記光学レンズの遠見視力部に対応するように、更なるゾーンを着用者の前記光学レンズの近見視力部に対応するように構成するステップを更に含む、請求項4〜8のいずれか一項に記載の方法。
- 入射光の透過を反射、屈折及び回折の少なくとも1つによって阻止するように、前記又は各選択的干渉フィルタリング手段を構成するステップを更に含む、請求項1〜9のいずれか一項に記載の方法。
- 前記第1の選択範囲が、430nm〜465nmの範囲内の波長を中心とする、10nm〜70nm、好ましくは、10nm〜60nmの範囲内の帯域幅を有する、請求項1〜10のいずれか一項に記載の方法。
- 前記第1の選択波長範囲が、実質的に435nm、445nm又は460nmの波長を中心とする、20nm〜60nm、好ましくは、20nm〜25nmの範囲内の帯域幅を有し、且つ前記第1の除去率が、10〜50%、好ましくは、30〜50%の範囲内である、請求項11に記載の方法。
- 前記第1の選択波長範囲が、実質的に435nm、445nm又は460nmの波長を中心とする、15nm〜30nm、好ましくは、15nm〜25nmの範囲内の帯域幅を有し、且つ前記第1の除去率が60〜100%、好ましくは、80〜100%の範囲内である、請求項11に記載の方法。
- 前記光デバイスが、前記全可視スペクトル内における可視光線の透過を40%〜92%の範囲内の阻止率において阻止するように構成されており、前記第1の選択波長範囲が、実質的に435nm、445nm又は460nmの波長を中心とする、25nm〜60nm、好ましくは、25nm〜35nmの範囲内の帯域幅を有し、且つ前記第1の除去率が前記第1の選択波長範囲の少なくとも5%の追加阻止を提供するように構成される、請求項11に記載の方法。
- 前記第1の選択波長範囲が465nm〜495nmのものである、請求項1〜10のいずれか一項に記載の方法。
- 前記第1の選択波長範囲が550nm〜660nmのものである、請求項1〜10のいずれか一項に記載の方法。
- 前記第1の選択波長範囲が、590nm〜650nm、好ましくは、615nm〜625nmのものである、請求項1〜10のいずれか一項に記載の方法。
- 前記第1の選択波長範囲が560nm〜600nmのものである、請求項1〜10のいずれか一項に記載の方法。
- 光学レンズを製造する方法であって、
未完成の表面と反対側の表面とを有する半完成の光学レンズであって、前記未完成の表面が凸面及び凹面のうちの1つであり、前記反対側の表面が凸面及び凹面のうちのもう一方である半完成の光学レンズを用意するステップと、
使用者の前記光学レンズのための選択的干渉フィルタリング手段の構成を決定するステップと、
前記未完成の表面を表面仕上げするステップと、
前記表面のうち1つを前記選択的干渉フィルタリング手段に設けるステップと、
を含み、
前記選択的干渉フィルタリング手段の構成を決定する前記ステップが請求項1〜17のいずれか一項に記載の選択的干渉フィルタリング手段の構成を決定する方法を含む、
方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306630.2 | 2011-12-08 | ||
EP11306630.2A EP2602653B1 (en) | 2011-12-08 | 2011-12-08 | Method of determining the configuration of an ophthalmic filter |
PCT/IB2012/057013 WO2013084176A1 (en) | 2011-12-08 | 2012-12-06 | Method of determining the configuration of an ophthalmic filter |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020075354A Division JP2020157071A (ja) | 2011-12-08 | 2020-04-21 | 眼科用フィルタの構成を決定する方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015509742A true JP2015509742A (ja) | 2015-04-02 |
JP2015509742A5 JP2015509742A5 (ja) | 2016-01-28 |
JP6773391B2 JP6773391B2 (ja) | 2020-10-21 |
Family
ID=47522763
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014545428A Active JP6773391B2 (ja) | 2011-12-08 | 2012-12-06 | 眼科用フィルタの構成を決定する方法 |
JP2020075354A Pending JP2020157071A (ja) | 2011-12-08 | 2020-04-21 | 眼科用フィルタの構成を決定する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020075354A Pending JP2020157071A (ja) | 2011-12-08 | 2020-04-21 | 眼科用フィルタの構成を決定する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10108027B2 (ja) |
EP (1) | EP2602653B1 (ja) |
JP (2) | JP6773391B2 (ja) |
KR (1) | KR102021004B1 (ja) |
CN (1) | CN104024924B (ja) |
AU (1) | AU2012348559B2 (ja) |
BR (1) | BR112014013839B1 (ja) |
WO (1) | WO2013084176A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015099364A (ja) * | 2013-11-18 | 2015-05-28 | エバーディスプレイ オプトロニクス(シャンハイ) リミテッド | 表示パネル及びその製造方法 |
WO2017175873A1 (ja) * | 2016-04-07 | 2017-10-12 | 株式会社坪田ラボ | やせるめがね |
JP2017533449A (ja) * | 2014-07-22 | 2017-11-09 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 |
JP2019502953A (ja) * | 2015-12-22 | 2019-01-31 | エシロール・アンテルナシオナル | 非視覚的生理作用を刺激する方法と眼科用エレメント |
JP2020530587A (ja) * | 2017-08-09 | 2020-10-22 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 |
US10914877B2 (en) | 2013-11-15 | 2021-02-09 | University Of Utah Research Foundation | Nanoparticle light filtering method and apparatus |
US11672944B2 (en) | 2011-01-17 | 2023-06-13 | University Of Utah Research Foundation | Methods, systems, and apparatus for modulating or reducing photophobic responses |
WO2023189098A1 (ja) * | 2022-03-30 | 2023-10-05 | 東京都公立大学法人 | 光の特性の決定方法 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014047724A1 (en) | 2012-09-26 | 2014-04-03 | Ledtech International Inc. | Multilayer optical interference filter |
US9110230B2 (en) | 2013-05-07 | 2015-08-18 | Corning Incorporated | Scratch-resistant articles with retained optical properties |
US9359261B2 (en) * | 2013-05-07 | 2016-06-07 | Corning Incorporated | Low-color scratch-resistant articles with a multilayer optical film |
US9366784B2 (en) | 2013-05-07 | 2016-06-14 | Corning Incorporated | Low-color scratch-resistant articles with a multilayer optical film |
CN103439802B (zh) * | 2013-09-04 | 2015-12-23 | 杏晖光学(厦门)有限公司 | 抗蓝光镜片的制作方法 |
CN103439804B (zh) * | 2013-09-04 | 2016-04-27 | 杏晖光学(厦门)有限公司 | 一种抗蓝光镜片 |
WO2015097169A1 (en) * | 2013-12-23 | 2015-07-02 | Essilor International (Compagnie Generale D'optique) | Head-mounted display with filter function |
US11267973B2 (en) | 2014-05-12 | 2022-03-08 | Corning Incorporated | Durable anti-reflective articles |
US9790593B2 (en) | 2014-08-01 | 2017-10-17 | Corning Incorporated | Scratch-resistant materials and articles including the same |
WO2016102083A2 (en) * | 2014-09-03 | 2016-06-30 | Essilor International (Compagnie Générale d'Optique) | An optical device |
TWI647521B (zh) * | 2014-09-29 | 2019-01-11 | 緯創資通股份有限公司 | 背光模組及具有其之顯示裝置 |
EP3241065A1 (en) * | 2014-12-30 | 2017-11-08 | Essilor International (Compagnie Générale d'Optique) | Management system and method of an active device |
FR3032283B1 (fr) * | 2015-02-02 | 2018-01-26 | Bnl Eurolens | Lentille ophtalmique, notamment pour lunettes de soleil |
CN104597621A (zh) * | 2015-02-10 | 2015-05-06 | 光驰科技(上海)有限公司 | 双面镀膜防蓝光树脂镜片 |
US10529899B2 (en) | 2015-07-10 | 2020-01-07 | Dexerials Corporation | Phosphor sheet, white light source device including the phosphor sheet, and display device including the white light source device |
CN105116564A (zh) * | 2015-08-19 | 2015-12-02 | 中国科学院深圳先进技术研究院 | 一种具有光子晶体结构色的隐形眼镜及其制备方法 |
EP3338140A1 (en) * | 2015-08-21 | 2018-06-27 | Essilor International | Active optical filter for spectacle lenses |
CN112213802A (zh) | 2015-09-14 | 2021-01-12 | 康宁股份有限公司 | 减反射制品以及包含其的显示器装置 |
WO2017058562A1 (en) * | 2015-10-02 | 2017-04-06 | 3M Innovative Properties Company | Optical filter |
KR102499750B1 (ko) | 2015-11-06 | 2023-02-15 | 에씰로 앙터나시오날 | 청색광으로부터 보호하는 광학 물품 |
CN105301798B (zh) * | 2015-12-15 | 2018-04-03 | 南昌益盾科技有限公司 | 一种防蓝光光学镜片 |
CN105372838B (zh) * | 2015-12-15 | 2018-05-04 | 龙南县生产力促进中心 | 一种具有复合防蓝光膜层的镜片 |
CN105334641B (zh) * | 2015-12-15 | 2018-04-03 | 南昌益盾科技有限公司 | 一种防蓝光镜片 |
JP2019525263A (ja) * | 2016-07-28 | 2019-09-05 | エイシーイー、ロナルド・エス. | 人の視覚向上のためにスペクトル的に彫刻された多重狭帯域フィルタ |
EP3507087A4 (en) | 2016-08-30 | 2020-04-29 | HUE.Al, LLC | OPTICAL DEVICE FOR IMPROVING HUMAN COLOR PERCEPTION |
CN114085038A (zh) | 2018-08-17 | 2022-02-25 | 康宁股份有限公司 | 具有薄的耐久性减反射结构的无机氧化物制品 |
WO2020187799A1 (en) * | 2019-03-18 | 2020-09-24 | Essilor International | Filter for eye cone cells protection |
EP3800626A1 (en) | 2019-10-03 | 2021-04-07 | Nokia Technologies Oy | Blue light reduction |
WO2021123858A1 (en) * | 2019-12-19 | 2021-06-24 | Essilor International | Screen friendly optical article |
US11994755B2 (en) | 2021-10-28 | 2024-05-28 | Rise Nano Optics Ltd. | Diffusion of nanoparticles into transparent plastic |
WO2024127055A1 (en) | 2022-12-16 | 2024-06-20 | Essilor International | Ophthalmic lens element with masking structures |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52109848U (ja) * | 1976-02-17 | 1977-08-20 | ||
JPS6084504A (ja) * | 1983-08-22 | 1985-05-13 | フア−ランド、オプテイカル、カンパニ−、インコ−ポレイテツド | 所定の波長の光に対して保護するための遮光器 |
JP2002303832A (ja) * | 2001-04-05 | 2002-10-18 | Seiko Epson Corp | 色覚異常者用眼鏡レンズ |
JP2010510535A (ja) * | 2006-11-17 | 2010-04-02 | エシロール アンテルナシオナル (コンパニー ジェネラレ ドプテイク) | マルチ−着色眼科用レンズ |
JP2010511205A (ja) * | 2006-11-28 | 2010-04-08 | ハイ・パフォーマンス・オプティクス・インコーポレーテッド | 改良型コントラスト感度を提供する高性能選択型光波長フィルタリング |
US20100149483A1 (en) * | 2008-12-12 | 2010-06-17 | Chiavetta Iii Stephen V | Optical Filter for Selectively Blocking Light |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4846913A (en) * | 1983-02-22 | 1989-07-11 | Optical Systems International Inc. | Method for making bifocal lens |
US4786125A (en) * | 1983-08-22 | 1988-11-22 | Farrand Optical Co. | Ocular protective apparatus |
DE3734438A1 (de) | 1987-10-12 | 1989-04-27 | Ver Glaswerke Gmbh | Verfahren zur herstellung eines reflexionshologramms |
US4942102A (en) | 1988-01-15 | 1990-07-17 | E. I. Du Pont De Nemours And Company | Holographic optical elements having a reflection hologram formed in a photopolymer |
US5024909A (en) | 1988-01-15 | 1991-06-18 | E. I. Du Pont De Nemours And Company | Dry film process for altering wavelength response of holograms |
DE3837008A1 (de) * | 1988-10-31 | 1990-05-03 | Zeiss Carl Fa | Lichtschutzfilter |
DE3837998A1 (de) * | 1988-11-09 | 1990-05-10 | Diehl Gmbh & Co | Verfahren zur simulation der auswirkung eines wirkungsfeldes |
US5016643A (en) * | 1990-05-02 | 1991-05-21 | Board Of Regents, The University Of Texas System | Vascular entoptoscope |
JP3852116B2 (ja) | 1995-11-24 | 2006-11-29 | セイコーエプソン株式会社 | 累進多焦点レンズ及び眼鏡レンズ |
US6955430B2 (en) | 2001-12-11 | 2005-10-18 | Pratt Steven G | Blue blocking lens |
CN2713500Y (zh) * | 2004-04-12 | 2005-07-27 | 温州众生科技有限公司 | 防蓝光伤害保健眼镜片 |
US7854505B2 (en) * | 2006-03-15 | 2010-12-21 | The Board Of Trustees Of The University Of Illinois | Passive and active photonic crystal structures and devices |
CA2705785A1 (en) * | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
WO2009048124A1 (ja) | 2007-10-10 | 2009-04-16 | Hoya Corporation | 累進屈折力レンズの製造方法、累進屈折力レンズ |
CN101414425B (zh) * | 2007-10-16 | 2013-07-17 | 宋学锋 | 显示装置及其显示方法 |
JP5448352B2 (ja) | 2008-03-10 | 2014-03-19 | 富士フイルム株式会社 | 着色硬化性組成物、カラーフィルタ、及び、固体撮像素子 |
US8690340B2 (en) | 2008-12-12 | 2014-04-08 | Texas Instruments Incorporated | Combined image projection and capture system using on and off state positions of spatial light modulator |
WO2010111499A1 (en) * | 2009-03-25 | 2010-09-30 | High Performance Optics, Inc. | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
CN101776776A (zh) | 2010-01-14 | 2010-07-14 | 北京大学第三医院 | 分色眼镜片及其制备方法 |
-
2011
- 2011-12-08 EP EP11306630.2A patent/EP2602653B1/en active Active
-
2012
- 2012-12-06 BR BR112014013839-7A patent/BR112014013839B1/pt active IP Right Grant
- 2012-12-06 KR KR1020147018696A patent/KR102021004B1/ko active IP Right Grant
- 2012-12-06 WO PCT/IB2012/057013 patent/WO2013084176A1/en active Application Filing
- 2012-12-06 US US14/363,948 patent/US10108027B2/en active Active
- 2012-12-06 AU AU2012348559A patent/AU2012348559B2/en active Active
- 2012-12-06 JP JP2014545428A patent/JP6773391B2/ja active Active
- 2012-12-06 CN CN201280060111.0A patent/CN104024924B/zh active Active
-
2020
- 2020-04-21 JP JP2020075354A patent/JP2020157071A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52109848U (ja) * | 1976-02-17 | 1977-08-20 | ||
JPS6084504A (ja) * | 1983-08-22 | 1985-05-13 | フア−ランド、オプテイカル、カンパニ−、インコ−ポレイテツド | 所定の波長の光に対して保護するための遮光器 |
JP2002303832A (ja) * | 2001-04-05 | 2002-10-18 | Seiko Epson Corp | 色覚異常者用眼鏡レンズ |
JP2010510535A (ja) * | 2006-11-17 | 2010-04-02 | エシロール アンテルナシオナル (コンパニー ジェネラレ ドプテイク) | マルチ−着色眼科用レンズ |
JP2010511205A (ja) * | 2006-11-28 | 2010-04-08 | ハイ・パフォーマンス・オプティクス・インコーポレーテッド | 改良型コントラスト感度を提供する高性能選択型光波長フィルタリング |
US20100149483A1 (en) * | 2008-12-12 | 2010-06-17 | Chiavetta Iii Stephen V | Optical Filter for Selectively Blocking Light |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672944B2 (en) | 2011-01-17 | 2023-06-13 | University Of Utah Research Foundation | Methods, systems, and apparatus for modulating or reducing photophobic responses |
US10914877B2 (en) | 2013-11-15 | 2021-02-09 | University Of Utah Research Foundation | Nanoparticle light filtering method and apparatus |
JP2015099364A (ja) * | 2013-11-18 | 2015-05-28 | エバーディスプレイ オプトロニクス(シャンハイ) リミテッド | 表示パネル及びその製造方法 |
JP2017533449A (ja) * | 2014-07-22 | 2017-11-09 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 |
JP2020190749A (ja) * | 2014-07-22 | 2020-11-26 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 |
JP2019502953A (ja) * | 2015-12-22 | 2019-01-31 | エシロール・アンテルナシオナル | 非視覚的生理作用を刺激する方法と眼科用エレメント |
JP7202183B2 (ja) | 2015-12-22 | 2023-01-11 | エシロール・アンテルナシオナル | 非視覚的生理作用を刺激する方法と眼科用エレメント |
WO2017175873A1 (ja) * | 2016-04-07 | 2017-10-12 | 株式会社坪田ラボ | やせるめがね |
JP2020530587A (ja) * | 2017-08-09 | 2020-10-22 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 |
JP2023082005A (ja) * | 2017-08-09 | 2023-06-13 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 |
WO2023189098A1 (ja) * | 2022-03-30 | 2023-10-05 | 東京都公立大学法人 | 光の特性の決定方法 |
Also Published As
Publication number | Publication date |
---|---|
BR112014013839A2 (pt) | 2017-06-13 |
CN104024924A (zh) | 2014-09-03 |
US20140320806A1 (en) | 2014-10-30 |
AU2012348559A1 (en) | 2014-07-17 |
EP2602653A1 (en) | 2013-06-12 |
EP2602653B1 (en) | 2020-09-16 |
US10108027B2 (en) | 2018-10-23 |
WO2013084176A1 (en) | 2013-06-13 |
BR112014013839A8 (pt) | 2017-06-13 |
BR112014013839B1 (pt) | 2022-01-11 |
KR102021004B1 (ko) | 2019-09-11 |
AU2012348559B2 (en) | 2015-07-09 |
CN104024924B (zh) | 2016-08-24 |
KR20140104997A (ko) | 2014-08-29 |
JP6773391B2 (ja) | 2020-10-21 |
JP2020157071A (ja) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6482018B2 (ja) | 眼科用フィルタ | |
JP2020157071A (ja) | 眼科用フィルタの構成を決定する方法 | |
JP2020204785A (ja) | 眼科用フィルタ | |
US8113651B2 (en) | High performance corneal inlay | |
JP2022025144A (ja) | 羞明反応の頻度および/または程度を低減する、または概日周期を調節する方法、システム、および装置 | |
CN111292615B (zh) | 提供改进的对比灵敏度的高性能选择性光波长过滤 | |
WO2008106449A1 (en) | High performance corneal inlay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151002 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20151002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151019 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20151013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151202 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151202 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151202 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180508 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180822 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180822 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20180910 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20181002 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20181002 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190315 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20190416 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20190820 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20191023 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200421 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200728 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200730 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20200811 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20200908 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20200908 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201001 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6773391 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |